openPR Logo
Press release

Global Antidiabetic Drugs Market - Product Segment Analysis And Forecast

07-17-2017 11:48 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: SA-BRC

Global Antidiabetic Drugs Market - Product Segment Analysis

Diabetes is a major lifestyle disorder affecting millions of individuals globally. The disorder is also linked with other complications such as diabetic retinopathy, diabetic foot ulcers, nephropathy and cardiovascular complications among others. Wide spread global prevalence and rising incidence rate has made the antidiabetic drugs market attractive for pharmaceutical drug manufacturers. Introduction of superior products in the recent past and increasing patient compliance are other factors driving the diabetes treatment market. Antidiabetic drugs pipeline, which is rich with potential candidates from leading players such as Pfizer, Novo Nordisk, Sanofi and others, is expected to feed new blockbuster drugs to the market in the near future.

Currently approved drug in the antidiabetic drugs market are categorized under classes including Sulfonylureas (Gliclazide, Glimepiride), Biguanides (Metformine), Thiazolidinediones (Pioglitazone, Rosiglitazone), Dipeptidyl- peptidase-4 (DPP-4) inhibitors (Linagliptine, Sitagliptine), Glucagon-like peptide-1 (GLP-1) agonist (Liraglutide) and Sodium glucose cotransporter-2 inhibitors (SGLT2) (Dapagliflozine, Canaglifozine). Apart from the aforementioned approved drugs, certain drug candidates currently in phase 3 are expected to receive regulatory approval during the forecast period. Pfizer and Merck recently announced positive phase 3 results for ertugliflozin (MK-8835), a sodium glucose co-transporter-2 (SGLT2) inhibitor. Lexicon Pharmaceuticals, Inc. also reported positive topline results in September 2016 for its candidate sotagliflozin. DiaMedica is currently testing potential candidate DM199 for the treatment of diabetic kidney disease. These new candidates would boost the global antidiabetic drugs market.

Request Free Report Sample@ www.sa-brc.com/Global-Antidiabetic-Drugs-Market-and-Pipel...

There exists high demand for diabetes drugs in the Asia Pacific region due to high prevalence. India is considered as a diabetes capital of the world with over 50 million type-2 diabetes patients; while China records 12% of the adult population suffering from diabetes. World Health Organization (WHO) estimates that over 80% of the diabetes mortalities occur in low and middle income countries. This indicates large unmet needs in such countries, where prolonged diabetes therapy is not affordable due to economic crises. According to data published by the World Bank, United States records diabetes prevalence in 10.8% of the population in age group 20 to 79 years, as against 9.3% in India and 9.8% in China. Another data published by the American Diabetes Association estimates total cost of diabetes in the U.S. in 2012 to over US$ 240 billion. The organization also estimates that 1.4 million individuals are diagnosed with diabetes every year in the U.S. alone. Such high prevalence and increasing incidence rate indicate rapid growth potential for the antidiabetic drugs market.

Key players in the antidiabetic drugs market include Pfizer, Inc., Novo Nordisk A/S, Sanofi S.A., Eli Lilly and Company, AstraZeneca plc, Johnson & Johnson, and others.

NOTE: This report is currently under research and will be made available to clients on request.

Go For Report TOC@ www.sa-brc.com/Global-Antidiabetic-Drugs-Market-and-Pipel...

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
Office No. 14,
Hermes Kunj, Mangaldas Road,
Pune, 411001
India
Phone: +91-02041210872
Email: support@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Antidiabetic Drugs Market - Product Segment Analysis And Forecast here

News-ID: 626643 • Views: 157

More Releases from SA-BRC

Biochip Market Analysis by Application and Trend 2017-2021
Biochips allow simultaneous testing of higher number of analytes to achieve high throughput and low cost per test. Nanotechnology has helped in miniaturization of devices to achieve higher performance standards. Microarrays are most important part of biochips which send signals to the biochip to deliver end results. Microfluidic biochips have become modern alternative to routine laboratories. Microfluidic technology which enables controlling flow of liquids in micro and pico quantities has
Acute Myeloid Leukemia Therapeutics Market Share, Analysis and Segments 2017-202 …
Acute myeloid leukemia is a cancer of blood cells and involves proliferation of abnormal blood cell types and subsequent replacement of bone marrow with cancerous cells. Major leukemia types include myeloblastic, promyeloctic, myelomonocytic, monocytic, erythroleukemia, megakaryocytic. Treatment of leukemia mainly depends on the type of leukemia and stage. Acute myeloid leukemia therapeutics market is rich with branded as well as generic drugs classified under various classes including antineoplastic agents, corticosteroids, tyrosine
Companion Diagnostics Market Share, Trends Analysis: 2017-2021
Companion diagnostics has revolutionized cancer therapeutics and enabled physicians to select specific treatment pattern from of myriad of drugs for cancer treatment. This has improved treatment outcome manyfold and has now become and indispensable part of personalized medicine. The companion diagnostics market received great attention post success of Herceptin (trastuzumab) and Gleevec (imatinib). Rapid adoption of companion diagnostics and supportive regulatory agencies have encouraged researchers to seek molecules that target
North America and Europe Bionic Eye Market Segment Analysis And Forecast: 2017-2 …
Sudden surge in bionic eye market was experienced recently after the National Health Service (NHS) announced the sponsorship to implant bionic eyes in ten patients. The bionic eye can help regain vision in individuals with visual impairment. Although currently two bionic eye systems has received regulatory approvals, other companies in the bionic eye market are also trying to develop new technology that can help in regaining visual sense in patients. The

All 5 Releases


More Releases for Antidiabetic

Oral Antidiabetic Treatment Market to Record Sturdy Growth by 2025
Diabetic is the condition where the sugar (glucose) level is high in the blood or the production of the insulin is inadequate. Diabetes main type the very first one is Type 1 and the second is Type 2, both the diabetic are most commonly find in the current scenario, apart from this many other diabetics case are also been listed as gestational diabetes and others. The world is moving
Oral Antidiabetic (OAD) Treatment Market Snapshot by 2017 – 2025
Diabetic is the condition where the sugar (glucose) level is high in the blood or the production of the insulin is inadequate. Diabetes main type the very first one is Type 1 and the second is Type 2, both the diabetic are most commonly find in the current scenario, apart from this many other diabetics case are also been listed as gestational diabetes and others. The world is moving toward
Antidiabetic Biosimilars Market Expected to Grow Globally
Antidiabetic biosimilars market overview Antidiabetics help control blood glucose levels in diabetic patients. Various types of antidiabetics include biguanides, thiazolidinediones, DPP-IV inhibitors, α-glucosidase Inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists such as exenatide. A biosimilar product is biological product that is approved on the basis that it is highly similar to a FDA approved biological product known as a reference product. Biosimilar manufacturers need to generate data from lab testing and
03-07-2017 | Health & Medicine
SA-BRC
Antidiabetic Drugs Market and Pipeline Assessment
Diabetes is a major lifestyle disorder affecting millions of individuals globally. The disorder is also linked with other complications such as diabetic retinopathy, diabetic foot ulcers, nephropathy and cardiovascular complications among others. Wide spread global prevalence and rising incidence rate has made the antidiabetic drugs market attractive for pharmaceutical drug manufacturers. Introduction of superior products in the recent past and increasing patient compliance are other factors driving the diabetes treatment
Global Antidiabetic Thiazolidinediones Market Research Report 2017
The research report on the global Antidiabetic Thiazolidinediones market studies the market in the past based on which estimates are presented for the future. The report looks into vital market indicators, trends, and opportunities that will have a bearing on the development of this market. The report begins with an outline of terms and terminologies, classifications, and applications that are standard conventions in the global Antidiabetic Thiazolidinediones market. A glance into
Antidiabetic Biosimilars Market, Company Analysis and Forecast to 2024
Antidiabetic biosimilars market overview Antidiabetics help control blood glucose levels in diabetic patients. Various types of antidiabetics include biguanides, thiazolidinediones, DPP-IV inhibitors, α-glucosidase Inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists such as exenatide. A biosimilar product is biological product that is approved on the basis that it is highly similar to a FDA approved biological product known as a reference product. Biosimilar manufacturers need to generate data from lab testing and